Journal of the Korean Cancer Association 1990;22(2): 286-298.
인체 신세포암과 방광암 세포주에 대한 림프킨 활성 살해 세포와 Interleukin - 2 활성 종양침윤 림프구의 항암효과에 대한 연구
이종욱, 이은식, 허대석, 박재갑
Antitumor Activity of Lymphokine Activated Killer Cells ( LAK ) and Interleukin-2 Activated Tumor Infiltrating Lymphocytes ( TIL ) to the Cell Lines of Human Renal cell carcinom
We analysed the antitumor activity of lymphokine activated killer cells (LAK) induced from peripheral bloods of normal, renai cells carcinoma and transitional cell carcinoma patients and interleukin-2 (IL-2) activated tumor infiltrating lymphocytes (TIL) from human renal cell carcinoma and transitional cell carcinoma of the bladder. An establidhed human renal cell carcinoma (Caki-1l and transitiunai cell carcinoma cell lines (T-24) were used as target cell. Cytotoxicity was checked by MTT assay. As a pilot study, concentration of IL-2 produced by KAIST was measured using IL-2 dependent CTLL cell compared with Cetus standard unit and optimun conditions for LAK generation were evaiuated. The concentration of IL-2 was 2 x 10(6) Cetus units/mg. The optimum target cell number was 5 x 10(3) cells in Caki-1 and 2.5 x 10(3) cells in T-24 cell line. Most active LAK cells were induced by 1,000 units,' m1 of IL-2 concentration and 5 days incubation period. The LAK activity of 10 normal adults (group 1), 10 renal celi carcinoma (group 2) and 9 transitional cell carcinoma patients lgroup 3) ta the target cells were compared. More than 50% of target cells were killed when effector; target cell ratio was 10 or more. The killing activities against the T-24 and Caki-1 cell lines were not different in all three groups. The tunwr infiltrating lymphocytes from 10 renal cell and 9 transitional cell carcinomas were activated with 1,000 units/ml of IL-2. TIL was activated in 7 of 19 tumor tissues. TIL from renal cell carcinoma showed good proliferating potential and nonspecific killing activity to the T-24 and Caki-l. The killing activity of TIL appeared to be somewhat stronger than LAK. Adoptive immunotherapy using LAK and TIL cauid provide a good therapeutic modality in the patients with advanced renai cell carcinoma and transitional cell carcinoma of the bladder.
PDF Links
Full text via DOI 
Download Citation 
